Hammond S A, Guebre-Xabier M, Yu J, Glenn G M
IOMAI Corporation, Gaithersburg MD, 20878, USA.
Crit Rev Ther Drug Carrier Syst. 2001;18(5):503-26.
Transcutaneous immunization (TCI) has emerged recently as a new method of vaccination that uses the skin. The simplicity of a patch-based immunization may obscure the potency of this strategy for immunostimulation because TCI allows the safe use of a wide variety of potent adjuvants. It is thought that these adjuvants activate Langerhans cells in the skin, which migrate to the draining lymph to orchestrate robust systemic immune responses. TCI represents a novel combination using established knowledge relating to skin penetration, the potency of adjuvant-based immunostimulation, and data showing that Langerhans cells are highly desirable targets because of their antigen-presenting cell function. The near-term challenge will be to take this promising insight into successful product development.
经皮免疫（TCI）最近已成为一种利用皮肤的新型疫苗接种方法。基于贴片的免疫接种方法简单，这可能掩盖了这种免疫刺激策略的效力，因为经皮免疫允许安全使用多种强效佐剂。据认为，这些佐剂可激活皮肤中的朗格汉斯细胞，这些细胞迁移至引流淋巴结以协调强大的全身免疫反应。经皮免疫代表了一种新颖的组合，它结合了有关皮肤渗透的现有知识、基于佐剂的免疫刺激的效力，以及数据表明朗格汉斯细胞因其抗原呈递细胞功能而成为非常理想的靶点。近期的挑战将是把这一有前景的见解转化为成功的产品开发。
